Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2009

View Archived Issues

New renin inhibitors disclosed in joint patent from GSK and Vitae

Kv1 potassium channel inhibitors with anxiolytic properties synthesized at Lectus Therapeutics

Novel anti-VEGF antibodies in development at Domantis

Bristol-Myers Squibb imparts glucokinase activators for type 2 diabetes

Betagenon initiates U.K. investigational medicinal product-enabling studies for BG-8702

Genzyme profiles pipeline progression

Novel sodium channel blockers with analgesic activity developed at AstraZeneca

GSK claims new CGRP receptor antagonists useful for treating migraine and cluster headache

New HIV RT inhibitors jointly developed by Gilead & Korea Research Institute of Chemical Technology

FDA requests Pro-Pharmaceuticals to conduct phase III trial of Davanat in colorectal cancer

BioMS Medical reports results of exploratory phase II dirucotide trial in MS

Revotar Biopharmaceuticals starts phase II bimosiamose 5% cream trial

Supernus initiates phase IIa SPN-810 trial in conduct disorder

NeuroSearch and GSK extend and expand drug discovery alliance

Small molecule blocks sonic hedgehog signaling

Bortezomib effective in treating renal transplant rejection

Santarus submits NDA for addition to Zegerid product portfolio

Progen directors unanimously recommend proposed merger with Avexa

GlaxoSmithKline and Genmab submit Arzerra BLA to FDA

Patient recruitment resumes in FibroGen's phase II oral FG-4592 trial

Pfizer discontinues phase III axitinib study

Shionogi enters into licensing agreement on peptide vaccines with OncoTherapy

EpiCept receives FDA permission to file NDA for Ceplene in AML

FDA approves Kapidex for the treatment of GERD and erosive esophagitis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...